Tag: NASDAQ: ABUS

Business

Arbutus Biopharma Corp (NASDAQ: ABUS) And Antios Therapeutics Enter Into A Partnership To Treat The Hepatitis B Virus (HBV) Infection

Arbutus Biopharma Corp (NASDAQ: ABUS) has announced that it has recently joined hands with Antios Therapeutics. The two companies have entered into a clinical collaboration is to evaluate a triple combination of Arbutus’ proprietary GalNAc delivered RNAi therapeutic, AB-729, Antios’ proprietary active site polymerase inhibitor nucleotide (ASPIN), ATI-2173, and Viread […]

Business

Arbutus Biopharma Corp (NASDAQ: ABUS) Displays New Particulars on AB-729 and AB-836 Lineups

Arbutus Biopharma Corp (NASDAQ: ABUS) today announced the demonstration of five summaries at the European Association for the Study of the Liver (EASL) International Liver CongressTM (ILC).  Summaries presented by Professor Man-Fung Yuen The synopses encompassed an oral late-breaker validation (Demonstration LBO-2764) by Professor Man-Fung Yuen, D.Sc., M.D., Ph.D., and […]